Moderator(s):
Hyo-Soo Kim, Pieter Smits
Panelist(s): Junya Ako, Aloke V. Finn, Joo-Yong Hahn, Young-Hoon Jeong, Chan Joon Kim, Michael S. Lee, Mamas Mamas, Yongwhi Park
Panelist(s): Junya Ako, Aloke V. Finn, Joo-Yong Hahn, Young-Hoon Jeong, Chan Joon Kim, Michael S. Lee, Mamas Mamas, Yongwhi Park
- Modulation of DAPT Duration: Risk-benefit of 1-year DAPT
Tullio Palmerini - Clopidogrel Monotherapy After Short-term DAPT in Patients who Underwent PCI using DES
Takeshi Kimura - P2Y12 Inhibitor or Asprin for Long-term Antiplatelet Management
Kyung Woo Park - Recommendation, Guided vs. Potent P2Y12 Inhibitor Therapy: Updated Evidence
Pieter Smits - Panel Discussion I
- Edoxaban vs. DAPT for Valve Thrombosis and Cerebral Thromboembolism After TAVR: Deep-Dive into ADAPT-TAVR Trial
Duk-Woo Park - Updated Evidence and Recommendation of Antithrombotic Therapy after TAVR
George D. Dangas - Next Novel Antithrombotic Drugs for ACS/PCI: Oral Factor XIa inhibitor or More
Roxana Mehran - BRIGHT-4 Trial; Bivalirudin with a Post-PCI High-Dose Infusion vs. Heparin Monotherapy During Primary PCI in STEMI
Gregg W. Stone - Panel Discussion II